Multiple Myeloma · line 4 · None
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 4 |
|---|---|
| Track | aggressive |
| Linked regimen | None |
| ID | IND-MM-4L-CILTACEL-CART |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-MM |
| Sources | SRC-ESMO-MM-2023 SRC-NCCN-MM-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. 4L+ aggressive-track BCMA CAR-T option for triple-class refractory MM. Missing entity flag: dedicated REG-CILTA-CEL — author in PROD-2. International referral pathway is dominant access barrier in Ukraine.
Used By
Indication
IND-MM-RR-3L-CILTACEL- IND-MM-RR-3L-CILTACEL